相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Dual inhibition of cannabinoid CB1 receptor and inducible NOS attenuates obesity-induced chronic kidney disease
Shiran Udi et al.
BRITISH JOURNAL OF PHARMACOLOGY (2020)
The therapeutic potential of second and third generation CB1R antagonists
Resat Cinar et al.
PHARMACOLOGY & THERAPEUTICS (2020)
Overview of cannabidiol (CBD) and its analogues: Structures, biological activities, and neuroprotective mechanisms in epilepsy and Alzheimer's disease
Han Li et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Activation of the cannabinoid receptor 2 increases renal perfusion
J. D. Pressly et al.
PHYSIOLOGICAL GENOMICS (2019)
Structure-Effect Relationships of Novel Semi-Synthetic Cannabinoid Derivatives
Marcus R. Goetz et al.
FRONTIERS IN PHARMACOLOGY (2019)
Modulation of Renal GLUT2 by the Cannabinoid-1 Receptor: Implications for the Treatment of Diabetic Nephropathy
Liad Hinden et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
Absence of cannabinoid 1 receptor in beta cells protects against high-fat/high-sugar diet-induced beta cell dysfunction and inflammation in murine islets
Isabel Gonzalez-Mariscal et al.
DIABETOLOGIA (2018)
Blockade of cannabinoid 1 receptor improves glucose responsiveness in pancreatic beta cells
Hanho Shin et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2018)
VCE-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation through PPARγ- and CB2 receptor-dependent pathways
Carmen del Rio et al.
BRITISH JOURNAL OF PHARMACOLOGY (2018)
Targeted inhibition of the type 2 cannabinoid receptor is a novel approach to reduce renal fibrosis
Lili Zhou et al.
KIDNEY INTERNATIONAL (2018)
Cannabinoid-1 receptor deletion in podocytes mitigates both glomerular and tubular dysfunction in a mouse model of diabetic nephropathy
Tony Jourdan et al.
DIABETES OBESITY & METABOLISM (2018)
Proximal Tubular Cannabinoid-1 Receptor Regulates Obesity-Induced CKD
Shiran Udi et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Dual therapy targeting the endocannabinoid system prevents experimental diabetic nephropathy
Federica Barutta et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2017)
Sativex in the management of multiple sclerosis-related spasticity: An overview of the last decade of clinical evaluation
Sabrina Giacoppo et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2017)
Targeting Cannabinoid Signaling in the Immune System: High-ly Exciting Questions, Possibilities, and Challenges
Attila Olah et al.
FRONTIERS IN IMMUNOLOGY (2017)
Cannabinoids and autoimmune diseases: A systematic review
Valeria Katchan et al.
AUTOIMMUNITY REVIEWS (2016)
The novel, orally available and peripherally restricted selective cannabinoid CB2 receptor agonist LEI-101 prevents cisplatin-induced nephrotoxicity
Partha Mukhopadhyay et al.
BRITISH JOURNAL OF PHARMACOLOGY (2016)
Blockade of cannabinoid 1 receptor improves GLP-1R mediated insulin secretion in mice
Isabel Gonzalez-Mariscal et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2016)
Current and future efforts toward the prevention of type 1 diabetes
Laura Jacobsen et al.
PEDIATRIC DIABETES (2016)
Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile
M. Gomez-Canas et al.
PHARMACOLOGICAL RESEARCH (2016)
The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-γ and CB2 pathways
Carmen del Rio et al.
SCIENTIFIC REPORTS (2016)
Human CB1 Receptor Isoforms, present in Hepatocytes and β-cells, are Involved in Regulating Metabolism
Isabel Gonzalez-Mariscal et al.
SCIENTIFIC REPORTS (2016)
Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor
R. B. Laprairie et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
Deficiency of cannabinoid receptor of type 2 worsens renal functional and structural abnormalities in streptozotocin-induced diabetic mice
Federica Barutta et al.
KIDNEY INTERNATIONAL (2014)
Qualitative and quantitative analysis of fibrosis in the kidney
Tim D. Hewitson et al.
NEPHROLOGY (2014)
Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes
Tony Jourdan et al.
NATURE MEDICINE (2013)
Review of the mechanism of cell death resulting from streptozotocin challenge in experimental animals, its practical use and potential risk to humans
Chinedum Ogbonnaya Eleazu et al.
JOURNAL OF DIABETES AND METABOLIC DISORDERS (2013)
Cannabinoids Induce Pancreatic β-Cell Death by Directly Inhibiting Insulin Receptor Activation
Wook Kim et al.
SCIENCE SIGNALING (2012)
Chronic kidney disease growth factors in renal fibrosis
Peter Boor et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2011)
Single dose streptozotocin-induced diabetes: considerations for study design in islet transplantation models
M. C. Deeds et al.
LABORATORY ANIMALS (2011)
Should peripheral CB1 cannabinoid receptors be selectively targeted for therapeutic gain?
George Kunos et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2009)
Role of NF-κB in β-cell death
Danielle Melloul
BIOCHEMICAL SOCIETY TRANSACTIONS (2008)
Cannabidiol arrests onset of autoimmune diabetes in NOD mice
Lola Weiss et al.
NEUROPHARMACOLOGY (2008)
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
Robin Christensen et al.
LANCET (2007)
Enantiomeric cannabidiol derivatives: synthesis and binding to cannabinoid receptors
LO Hanus et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2005)
(+)-Cannabidiol analogues which bind cannabinoid receptors but exert peripheral activity only
E Fride et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2004)
Δ9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells
M Yuan et al.
JOURNAL OF NEUROIMMUNOLOGY (2002)
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide
T Bisogno et al.
BRITISH JOURNAL OF PHARMACOLOGY (2001)
分享论文
